A large NHS‑backed trial of the Galleri blood test, which scans for more than 50 cancers, found it can spot tumours months before symptoms appear.. The study, which screened over 142,000 adults aged 50 to 77, suggests the test could avert one in five late‑stage diagnoses and potentially save up to 30,000 lives annually in the United Kingdom.

Galleri test cuts emergency‑room cancer diagnoses by 25%

According to the trial data, the use of Galleri alongside existing screening programmes reduced cancers first identified in emergency departments by a quarter. Emergency detection typically means patients are already severely ill , so this shift could dramatically improve survival odds for thousands of patients.

One in 100 participants flagged, 52% confirmed cancers

The study reported that roughly 1% of the 142,000 participants received a positive Galleri result, and in just over half of those cases (52%) a cancer diagnosis was later confirmed. This detection rate, while modest in absolute terms, represents four times more cancers identified than with current screening alone, as noted by the researchers.

Potential to save up to 30,000 lives annually

Doctors involved in the research estimate that nationwide rollout could pervent up to 30,000 deaths each year, a figure derived from the test’s ability to catch cancers before they reach stage four. Sir Harpal Kumar, Chief Scientific Officer at Grail, called the findings “extremely important” and highlighted the move from reactive to proactive cancer care.

Stage‑four oesophageal detections drop 57% with Galleri

The trial showed a striking 57% reduction in stage‑four oesophageal cancer detections and more than a 33% fall in stage‑four bowel cancers. At the same time, diagnoses of stage‑three disease rose, giving patients a significantly better chance of five‑year survival.

Will NHS fund nationwide rollout?

While the results are promising, the report does not detail how the NHS plans to finance a country‑wide implementation.. Questions remain about cost‑effectiveness, integration with existing pathways, and whether the test will be offered to all eligible age groups or only high‑risk populations.